NeuroSense Therapeutics (NRSN) Receivables (2020 - 2023)
NeuroSense Therapeutics (NRSN) posted Receivables of $472000.0 for Q4 2023, down 7.45% sequentially from $510000.0 in Q4 2022, and down 7.45% YoY from $510000.0 in Q4 2022.
NeuroSense Therapeutics (NRSN) Receivables (2020 - 2023) Analysis & Trends
NeuroSense Therapeutics has reported Receivables for 4 years, with the latest figure at $472000.0 in Q4 2023.
- Quarterly Receivables fell 7.45% year-over-year to $472000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $472000.0 (down 7.45% YoY) and the FY2023 annual result came in at $472000.0, down 7.45% from the prior year.
- Receivables declined to $472000.0 in Q4 2023 per NRSN's latest filing, from $510000.0 in the prior quarter.
- Over five years, Receivables peaked at $620000.0 in Q4 2021 and troughed at $60000.0 in Q4 2020.
- A 4-year average of $415500.0 and a median of $491000.0 in 2022 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2022: Receivables soared 933.33% in 2021, then decreased 17.74% in 2022.
- Over 4 years, Receivables stood at $60000.0 in 2020, then jumped by 933.33% to $620000.0 in 2021, then retreated by 17.74% to $510000.0 in 2022, then declined by 7.45% to $472000.0 in 2023.
- According to Business Quant data, Receivables over the past three periods registered $472000.0, $510000.0, and $620000.0 for Q4 2023, Q4 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NeuroSense Therapeutics | 9.68 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 472,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Dec 31, 2021 | 620,000.00 |
| Dec 31, 2020 | 60,000.00 |